Management of Fibromyalgia Syndrome: Review of Evidence
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Fibromyalgia syndrome (FMS) is a common chronic musculoskeletal pain disorder of unknown etiology and characterized by generalized body pain, hyperalgesia, and other functional and emotional comorbidities. Despite extensive research, no treatment modality is effective for all FMS patients. In this paper, we briefly review the history of FMS and diagnostic criteria, and potential pathophysiological mechanisms including central pain modulation, neurotransmitters, sympatho-adrenal and hypothalamic-pituitary-adrenal systems and peripheral muscle issues. The primary focus of the paper is to review treatment options for managing fibromyalgia symptoms. We will discuss FDA-approved medications and other pharmacologic agents, and non-pharmacologic treatments that have shown promising effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central sensitization: implications for the diagnosis and treatment of pain
Woolf, C. J. (2011) · Pain · doi:10.1016/j.pain.2010.09.030 · Cited by 4,771
Wolfe, F., Clauw, D. J., Fitzcharles, M., Goldenberg, D. L., Katz, R. S., Mease, P., Russell, A. S., Russell, I. J., Winfield, J. B., & Yunus, M. B. (2010) · Arthritis Care & Research · doi:10.1002/acr.20140 · Cited by 3,952 · cited 1×
“In order to address these concerns, new diagnostic criteria for FMS were proposed recently, based on data from another multicenter study [17].”
BackgroundFunctional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia
Gracely, R. H., Petzke, F., Wolf, J. M., & Clauw, D. J. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10225 · Cited by 1,263 · cited 1×
“Cortical activities in response to noxious stimulation are exaggerated in patients with FMS [19, 23, 24].”
BackgroundPrimary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls
Yunus, M., Masi, A. T., Calabro, J. J., Miller, K. A., & Feigenbaum, S. L. (1981) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(81)90096-2 · Cited by 910 · cited 1×
“The assumption persisted until systematic scientific studies began to appear in the literature in the 1970s, when an underlying inflammation was ruled out and a more neutral term fibromyalgia proposed [6, 7].”
BackgroundArnold, L. M., Lu, Y., Crofford, L. J., Wohlreich, M., Detke, M. J., Iyengar, S., & Goldstein, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20485 · Cited by 624 · cited 1×
“Double-blind RCTs evaluating duloxetine doses ranging between 60 and 120 mg per day have typically shown greater improvement in pain reports and self-report functioning than those in the placebo arm [60–62].”
BackgroundMultidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes
Scascighini, L., Toma, V., Dober-Spielmann, S., & Sprott, H. (2008) · Rheumatology · doi:10.1093/rheumatology/ken021 · Cited by 613 · cited 1×
“A systematic review [116] points to the methodological weakness, yet provides some evidence of the effectiveness of the approach for various”
BackgroundHypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia
Crofford, L. J., Pillemer, S. R., Kalogeras, K. T., Cash, J. M., Michelson, D., Kling, M. A., Sternberg, E. M., Gold, P. W., Chrousos, G. P., & Wilder, R. L. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371105 · Cited by 508
Grossman, P., Tiefenthaler-Gilmer, U., Raysz, A., & Kesper, U. (2007) · Psychotherapy and Psychosomatics · doi:10.1159/000101501 · Cited by 505
Arnold, L. M., Rosen, A., Pritchett, Y. L., D'Souza, D. N., Goldstein, D. J., Iyengar, S., & Wernicke, J. F. (2005) · Pain · doi:10.1016/j.pain.2005.06.031 · Cited by 471 · cited 1×
“1 Percentage of patients reporting [30% pain reduction by dose for pregabalin [56], duloxetine [60], and milnacipran [69] versus placebo.”
BackgroundBennett, R. M., Kamin, M., Karim, R., & Rosenthal, N. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00116-5 · Cited by 403
Cited by
Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives
Galvez-Sánchez, C. M., & Reyes del Paso, G. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041219 · Cited by 241
Grayston, R., Czanner, G., Elhadd, K., Goebel, A., Frank, B., Üçeyler, N., Malik, R. A., & Alam, U. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.08.003 · Cited by 213
Murai, N., Kondo, Y., Akuzawa, S., Mihara, T., Shiraishi, N., Kakimoto, S., & Matsumoto, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172750 · Cited by 34
Martínez, M. P., Sánchez, A. I., Prados, G., Lami, M. J., Villar, B., & Miró, E. (2021) · The Spanish Journal of Psychology · doi:10.1017/sjp.2021.30 · Cited by 24
Moshrif, A., Mosallam, A., Abu-Zaid, M. H., & Gouda, W. (2023) · Journal of Pain Research · doi:10.2147/jpr.s381314 · Cited by 12
“In the same context, the subjective nature of the disease and the absence of validated diagnostic tests negatively impact its management and lead to more delayed diagnosis (DD) with more socioeconomic impairment.(10) However, there is still a lack of studies about the effect of DD on the disease status and patients’ s…”
Background
Metadata
- Authors
- Okifuji, A., & Hare, B. D.
- Venue
- Pain and Therapy
- Published
- 2013-09-21
- Volume
- 2
- Issue
- 2
- Pages
- 87-104
- ISSN
- 2193-651X (ISSN-L)
- 2193-8237
- OpenAlex
- W2072075553
- Cited by
- 49
- References
- 30
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of Fibromyalgia Syndrome: Review of Evidence. https://app.cochat.ai/papers/10.1007/s40122-013-0016-9
- The paper
- Okifuji, A., & Hare, B. D. (2013). Management of Fibromyalgia Syndrome: Review of Evidence. Pain and Therapy. https://doi.org/10.1007/s40122-013-0016-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.